An advocacy group is suing the Trump administration for failing to disclose details of a settlement with Gilead over patent ...

HIV vaccine efforts have been slowed by the difficulty of getting neutralizing antibodies to target the correct locations of ...

Results from early-stage trial show that 80% of participants who received one of two HIV vaccine candidates produced antibodies against viral proteins.

Introduction Burden of non-communicable diseases (NCDs) continues to rise in low- and middle-income countries like Kenya. People with HIV (PWH) may be at greater risk for obesity and NCDs. National ...

Scientific breakthroughs take center stage at the International AIDS Society Conference as global HIV funding and political support erode.

With Black women and straight men increasingly at risk, Gilead’s Yeztugo may finally offer a discreet, stigma-free way to ...

Several vaccines for HIV have been tested in animal studies and an early safety trial in people, showing promising results in ...

Scientists used a mRNA-based vaccine to reliably trigger antibodies that block HIV infection in people and monkeys ...

We may be a step closer to a highly effective mRNA vaccine against HIV, but tests so far reveal that the approach can cause ...

This story first appeared in the UNAIDS Global AIDS Update 2025 report.

Healio received an APEX award for a 2024 report on the cloudy future of HIV vaccine research in the age of long-acting ...

Quality of life in people living with HIV was lower in those who had weight gain from adherence to antiretroviral therapy.